Source document

Bioclinica Transforms Source Document Management in Clinical Trials

Retrieved on: 
Tuesday, April 13, 2021
Clinical research, Health sciences, Health, Medical research, Pharmaceutical industry, Clinical trials, Clinical data management, Contract research organizations, Source document, Pharmacovigilance, Medical imaging, ERT

b'PRINCETON, N.J., April 13, 2021 /PRNewswire/ --Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today launched Source Document Manager .

Key Points: 
  • b'PRINCETON, N.J., April 13, 2021 /PRNewswire/ --Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today launched Source Document Manager .
  • This comprehensive solution enables clinical trial sponsors and contract research organizations (CROs) to collect, de-identify, translate, organize, and manage source documents seamlessly using a secure, cloud-based application.
  • "\nBioclinica Source Document Manager supports onlineprotected health information redaction at the site level with verification by a team of quality control experts and boasts direct integration with a premier online translation service to translate source documents.
  • Through deep medical, scientific, and technology expertise, the company provides medical imaging and cardiac safety services, clinical endpoint adjudication, clinical trial software, and drug safety solutions.

Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval

Retrieved on: 
Thursday, February 11, 2021
Clinical research, Pharmaceutical industry, Health sciences, Health, Medical research, Clinical trial, Source document

"Protocol First will enable us to complete clinical trial site remote monitoring and source document verification by the end of March" stated Thomas Smeenk, CEO.

Key Points: 
  • "Protocol First will enable us to complete clinical trial site remote monitoring and source document verification by the end of March" stated Thomas Smeenk, CEO.
  • "Hemostemix needed a regulatory solution that could be deployed rapidly and provide immediate operational relief to the difficult task of source document verification.
  • We are very happy to provide such a solution and help Hemostemix in this critical process " said Hugh P. Levaux, Ph.D., Founder and CEO for Protocol First.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.